319416770	319416770	CD	B-NP	O
|	|	NNP	I-NP	O
SHUAH	SHUAH	NNP	I-NP	O
|	|	VBD	B-VP	O
43811510	43811510	CD	B-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
258001	258001	CD	B-NP	O
|	|	CC	I-NP	O
10/17/2000	10/17/2000	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
VOMITING	VOMITING	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Signed	Signed	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
DIS	DIS	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
8/6/2000	8/6/2000	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Signed	Signed	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
7/6/2000	7/6/2000	CD	B-NP	O
PRINCIPAL	PRINCIPAL	JJ	I-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
:	:	:	O	O
VOMITING	VOMITING	NN	B-NP	O
.	.	.	O	O

HISTORY	HISTORY	NN	B-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
52-year-old	52-year-old	JJ	I-NP	O
female	female	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
past	past	JJ	I-NP	O
medical	medical	JJ	I-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
diabetes	diabetes	NN	B-NP	O
and	and	CC	I-NP	O
hypertension	hypertension	NN	I-NP	O
who	who	WP	B-NP	O
was	be	VBD	B-VP	O
recently	recently	RB	I-VP	O
admitted	admit	VBN	I-VP	O
from	from	IN	B-PP	O
October	October	NNP	B-NP	O
,	,	,	O	O
2000	2000	CD	B-NP	O
through	through	IN	B-PP	O
July	July	NNP	B-NP	O
,	,	,	O	O
2000	2000	CD	B-NP	O
with	with	IN	B-PP	O
abdominal	abdominal	JJ	B-NP	O
pain	pain	NN	I-NP	O
diagnosed	diagnose	VBN	B-VP	O
with	with	IN	B-PP	O
diverticulitis	diverticulitis	NN	B-NP	O
,	,	,	O	O
treated	treat	VBN	B-VP	O
with	with	IN	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
,	,	,	I-NP	O
ampicillin	ampicillin	NN	I-NP	O
and	and	CC	I-NP	O
Flagyl	Flagyl	NN	I-NP	O
and	and	CC	O	O
discharged	discharged	JJ	B-NP	O
home	home	NN	I-NP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
subsequently	subsequently	RB	B-ADVP	O
,	,	,	O	O
she	she	PRP	B-NP	O
began	begin	VBD	B-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
several	several	JJ	B-NP	O
episodes	episode	NNS	I-NP	O
of	of	IN	B-PP	O
vomiting	vomiting	NN	B-NP	O
that	that	WDT	B-NP	O
was	be	VBD	B-VP	O
initially	initially	RB	B-ADJP	O
clear	clear	JJ	I-ADJP	O
and	and	CC	O	O
then	then	RB	O	O
turned	turn	VBD	B-VP	O
brown	brown	VBN	I-VP	O
with	with	IN	B-PP	O
some	some	DT	B-NP	O
dark	dark	JJ	I-NP	O
blood	blood	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
morning	morning	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
denies	deny	VBZ	B-VP	O
any	any	DT	B-NP	O
bright	bright	JJ	I-NP	O
red	red	JJ	I-NP	O
blood	blood	NN	I-NP	O
per	per	IN	B-PP	O
rectum	rectum	NN	B-NP	O
or	or	CC	O	O
melena	melena	NN	B-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
the	the	DT	B-NP	O
emergency	emergency	NN	I-NP	O
department	department	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
negative	negative	JJ	I-NP	O
NG	NG	NN	I-NP	O
lavage	lavage	NN	I-NP	O
and	and	CC	O	O
treated	treat	VBN	B-VP	O
with	with	IN	B-PP	O
Compazine	Compazine	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
seen	see	VBN	I-VP	O
by	by	IN	B-PP	O
Surgery	Surgery	NNP	B-NP	O
whose	whose	WP$	B-NP	O
initial	initial	JJ	I-NP	O
assessment	assessment	NN	I-NP	O
was	be	VBD	B-VP	O
Flagyl	Flagyl	NN	B-NP	O
related	related	JJ	I-NP	O
emesis	emesis	NN	I-NP	O
and	and	CC	O	O
changing	change	VBG	B-VP	O
antibiotics	antibiotic	NNS	B-NP	O
to	to	TO	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
and	and	CC	I-NP	O
clindamycin	clindamycin	NN	I-NP	O
.	.	.	O	O

Gastrointestinal	Gastrointestinal	NNP	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
consulted	consult	VBN	I-VP	O
who	who	WP	B-NP	O
felt	feel	VBD	B-VP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
blood	blood	NN	I-NP	O
was	be	VBD	B-VP	O
most	most	RBS	B-ADVP	O
likely	likely	RB	I-ADVP	O
from	from	IN	B-PP	O
a	a	DT	B-NP	O
Mallory-Weiss	Mallory-Weiss	JJ	I-NP	O
tear	tear	NN	I-NP	O
.	.	.	O	O

PAST	PAST	NNP	B-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
Diabetes	Diabete	NNS	B-NP	O
,	,	,	O	O
hypertension	hypertension	NN	B-NP	O
,	,	,	O	O
anemia	anemia	NN	B-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
cholecystectomy	cholecystectomy	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
appendectomy	appendectomy	NN	I-NP	O
,	,	,	O	O
small	small	JJ	B-NP	O
bowel	bowel	NN	I-NP	O
obstruction	obstruction	NN	I-NP	O
,	,	,	O	O
bilateral	bilateral	JJ	B-NP	O
cataracts	cataract	NNS	I-NP	O
,	,	,	O	O
bilateral	bilateral	JJ	B-NP	O
tubal	tubal	JJ	I-NP	O
ligation	ligation	NN	I-NP	O
,	,	,	O	O
diverticulitis	diverticulitis	NN	B-NP	O
,	,	,	O	O
chronic	chronic	JJ	B-NP	O
renal	renal	JJ	I-NP	O
failure	failure	NN	I-NP	O
.	.	.	O	O

PHYSICAL	PHYSICAL	NNP	B-NP	O
EXAMINATION	EXAMINATION	NNP	I-NP	O
:	:	:	O	O
VITAL	VITAL	JJ	B-NP	O
SIGNS	SIGNS	NN	I-NP	O
:	:	:	O	O
Temperature	Temperature	NN	B-NP	B-protein
99.4	99.4	CD	I-NP	I-protein
,	,	,	O	O
heart	heart	NN	B-NP	O
rate	rate	NN	I-NP	O
88	88	CD	I-NP	O
,	,	,	O	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
156/116	156/116	CD	I-NP	O
sitting	sit	VBG	B-VP	O
,	,	,	O	O
standing	stand	VBG	B-VP	O
169/74	169/74	CD	B-NP	O
.	.	.	O	O

ABDOMEN	ABDOMEN	NN	B-NP	O
:	:	:	O	O
Bowel	Bowel	NNP	B-NP	O
sounds	sound	VBZ	B-VP	O
positive	positive	JJ	B-NP	O
,	,	,	I-NP	O
soft	soft	JJ	I-NP	O
and	and	CC	O	O
non-tender	non-tender	JJ	B-ADJP	O
and	and	CC	I-ADJP	O
non-distended	non-distended	JJ	I-ADJP	O
.	.	.	O	O

RECTAL	RECTAL	NN	B-NP	O
:	:	:	O	O
Guaiac	Guaiac	NN	B-NP	O
negative	negative	JJ	B-ADJP	O
.	.	.	O	O

LABORATORY	LABORATORY	NN	B-NP	O
:	:	:	O	O
White	White	JJ	B-NP	O
blood	blood	NN	I-NP	O
cell	cell	NN	I-NP	O
count	count	NN	I-NP	O
was	be	VBD	B-VP	O
7.7	7.7	CD	B-NP	O
,	,	,	O	O
hematocrit	hematocrit	NN	B-NP	B-protein
36.2	36.2	CD	I-NP	I-protein
,	,	,	O	O
platelet	platelet	NN	B-NP	B-protein
count	count	NN	I-NP	I-protein
315	315	CD	I-NP	I-protein
.	.	.	O	O

INR	INR	NN	B-NP	B-protein
was	be	VBD	B-VP	O
1.2	1.2	CD	B-NP	O
,	,	,	O	O
PTT	PTT	NN	B-NP	B-protein
26.6	26.6	CD	I-NP	I-protein
.	.	.	O	O

BUN	BUN	NN	B-NP	O
and	and	CC	I-NP	O
creatinine	creatinine	NN	I-NP	O
were	be	VBD	B-VP	O
36	36	CD	B-NP	O
and	and	CC	I-NP	O
4.4	4.4	CD	I-NP	O
respectively	respectively	RB	B-ADVP	O
.	.	.	O	O

Amylase	Amylase	NN	B-NP	B-protein
was	be	VBD	B-VP	O
56	56	CD	B-NP	O
,	,	,	O	O
lipase	lipase	NN	B-NP	O
151	151	CD	I-NP	O
,	,	,	O	O
total	total	JJ	B-NP	O
bilirubin	bilirubin	NN	I-NP	O
0.3	0.3	CD	I-NP	O
,	,	,	O	O
alkaline	alkaline	NN	B-NP	O
phosphatase	phosphatase	NN	I-NP	O
103	103	CD	I-NP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
:	:	:	O	O
Because	Because	IN	B-PP	O
of	of	IN	I-PP	O
persistent	persistent	JJ	B-NP	O
nausea	nausea	NN	I-NP	O
and	and	CC	I-NP	O
vomiting	vomiting	NN	I-NP	O
despite	despite	IN	B-PP	O
having	have	VBG	B-VP	O
stopped	stop	VBD	I-VP	O
the	the	DT	B-NP	O
Flagyl	Flagyl	NN	I-NP	O
and	and	CC	O	O
decreased	decrease	VBN	B-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
on	on	IN	B-PP	O
April	April	NNP	B-NP	O
,	,	,	O	O
2000	2000	CD	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
levofloxacin	levofloxacin	NN	I-NP	O
was	be	VBD	B-VP	O
discontinued	discontinue	VBN	I-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
gastric	gastric	JJ	I-NP	O
emptying	emptying	NN	I-NP	O
study	study	NN	I-NP	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
within	within	IN	B-PP	O
normal	normal	JJ	B-NP	O
limits	limit	NNS	I-NP	O
and	and	CC	O	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
show	show	VB	I-VP	O
any	any	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
gastroparesis	gastroparesis	NN	B-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
January	January	NNP	B-NP	O
,	,	,	O	O
2000	2000	CD	B-NP	O
,	,	,	O	O
an	an	DT	B-NP	O
upper	upper	JJ	I-NP	O
endoscopy	endoscopy	NN	I-NP	O
was	be	VBD	B-VP	O
done	do	VBN	I-VP	O
that	that	WDT	B-NP	O
revealed	reveal	VBD	B-VP	O
two	two	CD	B-NP	O
discrete	discrete	JJ	I-NP	O
esophageal	esophageal	JJ	I-NP	O
ulcerations	ulceration	NNS	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
distal	distal	JJ	I-NP	O
esophagus	esophagus	NN	I-NP	O
with	with	IN	B-PP	O
surrounding	surround	VBG	B-VP	O
esophageal	esophageal	JJ	B-NP	O
erythema	erythema	NN	I-NP	O
,	,	,	O	O
most	most	RBS	B-ADVP	O
likely	likely	RB	I-ADVP	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
pill	pill	NN	B-NP	O
esophagitis	esophagitis	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
Prilosec	Prilosec	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
and	and	CC	I-NP	O
antibiotics	antibiotic	NNS	I-NP	O
were	be	VBD	B-VP	O
stopped	stop	VBN	I-VP	O
at	at	IN	B-PP	O
that	that	DT	B-NP	O
time	time	NN	I-NP	O
as	as	IN	B-SBAR	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
completed	complete	VBN	I-VP	O
a	a	DT	B-NP	O
ten	ten	CD	I-NP	O
day	day	NN	I-NP	O
course	course	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
also	also	RB	B-ADVP	O
had	have	VBD	B-VP	O
problems	problem	NNS	B-NP	O
with	with	IN	B-PP	O
hypertension	hypertension	NN	B-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
200s	200s	CD	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
labetalol	labetalol	NN	B-NP	O
.	.	.	O	O

Renal	Renal	JJ	B-NP	O
MRI	MRI	NN	I-NP	O
study	study	NN	I-NP	O
was	be	VBD	B-VP	O
done	do	VBN	I-VP	O
that	that	WDT	B-NP	O
was	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
for	for	IN	B-PP	O
renal	renal	JJ	B-NP	O
artery	artery	NN	I-NP	O
stenosis	stenosis	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
discharged	discharge	VBN	I-VP	O
home	home	NN	B-ADVP	O
in	in	IN	B-PP	O
stable	stable	JJ	B-NP	O
condition	condition	NN	I-NP	O
.	.	.	O	O

MEDICATIONS	MEDICATIONS	NNS	B-NP	O
ON	ON	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
:	:	:	O	O
Lasix	Lasix	NN	B-NP	O
160	160	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
day	day	NN	I-NP	O
,	,	,	O	O
NPH	NPH	NN	B-NP	B-protein
40	40	CD	B-NP	I-protein
units	unit	NNS	I-NP	I-protein
subcutaneously	subcutaneously	RB	B-VP	O
q.	q.	VBG	I-VP	O
AM	AM	NN	B-NP	O
,	,	,	O	O
regular	regular	JJ	B-NP	O
insulin	insulin	NN	I-NP	O
10	10	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-VP	O
q.	q.	VBG	I-VP	O
AM	AM	NN	B-NP	O
,	,	,	O	O
lisinopril	lisinopril	VBP	B-VP	O
20	20	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
Lopressor	Lopressor	NN	B-NP	O
50	50	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
Norvasc	Norvasc	NNP	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
Avandia	Avandia	NNP	B-NP	O
2	2	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
and	and	CC	O	O
Prilosec	Prilosec	VBP	B-VP	O
20	20	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
Dictated	Dictated	NNP	B-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
MERLE	MERLE	NNP	B-NP	O
BAAS	BAAS	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
VC49	VC49	NNP	I-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
THEO	THEO	NNP	B-NP	O
LAJOYE	LAJOYE	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
UP83	UP83	NNP	I-NP	O
RO446/637338	RO446/637338	NNP	I-NP	O
Batch	Batch	NNP	I-NP	O
:	:	:	O	O
65789	65789	CD	B-NP	O
Index	Index	NNP	I-NP	O
No	No	NNP	I-NP	O
.	.	.	O	O

TXKFG69UKO	TXKFG69UKO	NN	B-NP	O
D	D	NN	I-NP	O
:	:	:	O	O
3/3/01	3/3/01	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
3/3/01	3/3/01	CD	B-NP	O

